Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Single Dose, Dose Ranging Study of Intravenous AAV5-GLA (AMT-191) in Adult Males With Classic Fabry Disease

NCT06270316 is registered in ClinicalTrials.gov with UniQure Biopharma B.V. as lead sponsor.

NCT NCT06270316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06270316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Single Dose, Dose Ranging Study of Intravenous AAV5-GLA (AMT-191) in Adult Males With Classic Fabry Disease
Lead sponsor
UniQure Biopharma B.V.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 5, 2024
Completion date
November 30, 2031
Enrollment
20 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

fabry disease